Abstract
Acute coronary syndrome (ACS) is considered a common cardiovascular disease, in which there is a blood supply reduction to the myocardium, mostly due to atherosclerosis in the coronary arteries. the present study was designed to detect serum markers in Acute coronary syndrome patients infected with COVID-19 in Baghdad Governorate, by evaluating the level of Interleukin-23(IL-23) and level of creatine kinase isoenzyme (CK-MB). Methods: A total of one hundred fifty participants were enrolled in the current study divided into three groups 50 patients with ACS and 50 ACS with COVID-19 patients, while 50 participants as apparently healthy controls. age and sex-matched as healthy controls were involved in the present study. The serum IL-23 and CK-MB levels were measured using an ELISA technique. Serum concentrations of IL-23 and CK-MB were significantly higher in ACS patients and ACS with COVID-19 patients compared to healthy controls (P≤0.01) also there was a highly significant difference at (P≥ 0.01) between ACS patients and ACS with COVID-19 patients. IL- 23 can be considered a biomarker for ACS patients and ACS with COVID-19 patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
